News

Results from study with Episealer® Knee implant accepted for presentation at German orthopaedic congress

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Knee preservation of the middle-aged patient – two-staged treatment combination of patient specific metal implant and osteotomy. A case series.”, by Priv.-Doz. Dr. med. Clemens Kösters, has been accepted for presentation at the 11th annual congress of the Deutschen Kniegesellschaft (DKG, the German Knee Society). The congress will take place in Munich, Germany, on November 18-19, 2022. The abstract reports on the clinical outcome for…

Resultat från studie med Episealer® Knäimplantat accepterade för presentation på australiensk och nyzeeländsk ortopedkongress

Episurf Medical (Nasdaq: EPIS B) meddelar idag att en vetenskaplig sammanfattning med titeln ”Episealer, a mini metal implant for chondral injuries in the knee. A prospective single surgeon case series”, har accepterats för en podiumpresentation vid The combined Australian and New Zealand Knee Societies meeting, som kommer att äga rum i Queenstown, Nya Zeeland, den 27 – 29 oktober 2022. Presentationen kommer att hållas av prof. Karl Eriksson från Södersjukhuset och Karolinska Institutet, Stockholm, Sverige.…

Results from study with Episealer® Knee implant accepted for presentation at Australian and New Zealand orthopaedic congress

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Episealer, a mini metal implant for chondral injuries in the knee. A prospective single surgeon case series”, has been accepted for a podium presentation at the combined Australian and New Zealand Knee Societies meeting, which will take place in Queenstown, New Zealand, on October 27 – 29, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute,…

New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled “A method for manufacturing an implant and an implant with two coatings”, is in the area of implant materials and coating characteristics related to Episurf Medical’s devices. “Increased patent protection to support our research and development work is much appreciated, especially in the US market for which we have multiple products in…

Nytt patentbeviljande i USA för Episurf Medical

Amerikanska patentverket USPTO har meddelat sin avsikt att bevilja ytterligare en av Episurf Medicals (NASDAQ: EPIS B) patentansökningar. Patentet, benämnt “A method for manufacturing an implant and an implant with two coatings”, är inom området för implantatsmaterial och ytbeläggningar som relaterar till Episurf Medicals produkter. ”Ökat patentskydd för att stödja vårt forsknings- och utvecklingsarbete är mycket uppskattat, särskilt på den amerikanska marknaden för vilken vi har flera produkter i vår pipeline”, kommenterar Katarina Flodström, COO,…

Episurf Medicals Episealer® knäimplantat inkluderade i brittiska NICE guidelines

Episurf Medical (NASDAQ: EPIS B) meddelar idag att brittiska National Institute for Health and Care Excellence (NICE) den 24 augusti har publicerat riktlinjer för interventionsförfaranden inom området IPG734 Focal resurfacing implants to treat articular cartilage damage in the knee, där Episurf Medicals Episealer® knäimplantat omfattas. Publiceringen följer efter en granskningsprocess baserad på relevant dokumentation och informationsinsamling från intressenter så som patienter och ortopeder, vilken har pågått under flera kvartal. NICE riktlinjer är evidensbaserade rekommendationer för…

Episurf Medical’s Episealer® Knee implants included in UK NICE guidelines

Episurf Medical (NASDAQ: EPIS B) today announces that the UK National Institute for Health and Care Excellence (NICE) has on August 24 published interventional procedures guidance on IPG734 Focal resurfacing implants to treat articular cartilage damage in the knee, where Episurf Medical’s Episealer® Knee implants are included. The publication follows a review of relevant documentation and stakeholder input, including patients and surgeons, that has been going on for several quarters. NICE guidelines are evidence-based recommendations…

New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint”, relates to surgical pre-planning and 3D-based assessment of joint lesions, and complements Episurf Medical’s earlier US patents within this field. “With this we get additional protection in the US within medical imaging and surgical pre-planning, not only…

Nytt patentbeviljande i USA för Episurf Medical

Amerikanska patentverket USPTO har meddelat sin avsikt att bevilja ytterligare en av Episurf Medicals (NASDAQ: EPIS B) patentansökningar. Patentet, benämnt “System and method for creating a decision support material indicating damage to an anatomical joint”, relaterar till kirurgisk förplanering och 3D-baserad bedömning av skador i leder och kompletterar Episurf Medicals tidigare USA-patentet inom detta område. ”Med detta får vi ytterligare skydd i USA inom medicinsk bildbehandling och kirurgisk förplanering, inte bara relaterat till bolagets implantat…